Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder

Klopfer, Kiara, Delahunt, Brett, Adamson, Michael and Samaratunga, Hemamali (2014) Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. Anticancer Research, 34 11: 6779-6784.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Author Klopfer, Kiara
Delahunt, Brett
Adamson, Michael
Samaratunga, Hemamali
Title Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder
Journal name Anticancer Research   Check publisher's open access policy
ISSN 0250-7005
1791-7530
Publication date 2014-11-01
Year available 2014
Sub-type Article (original research)
Volume 34
Issue 11
Start page 6779
End page 6784
Total pages 6
Place of publication Attiki, Greece
Publisher International Institute of Anticancer Research
Collection year 2015
Language eng
Formatted abstract
Background:
Urothelial carcinoma (UC) variants can be difficult to differentiate from carcinoma metastatic to the bladder.

Materials and Methods:
We examined immunostaining for uroplakin III in 43 cases of primary bladder UC variants including micropapillary UC (n=19), nested variant of UC (n=2), pleomorphic giant-cell carcinoma (n=8), plasmacytoid UC (n=4), lymphoepithelioma-like carcinoma (n=2), large cell undifferentiated carcinoma (n=2), UC with abundant myxoid stroma (n=3) and lipid cell variant (n=3) and in 11 tumors from other organs metastatic to the bladder. These tumors included invasive ductal carcinoma of the breast (n=2), colorectal adenocarcinoma (n=4), endometrioid adenocarcinoma (n=1) and serous papillary carcinoma of the uterus (n=1) melanoma (n=1), embryonal carcinoma of the testis (n=1), and renal clear cell carcinoma (n=1).

Results:
Out of the 43 UC variants, 35 (81%) were positive for uroplakin III, including micropapillary, lipid cell variant and UC with abundant myxoid stroma. Pleomorphic giant cell carcinoma, plasmacytoid UC and nested variant of UC were less commonly positive. Of the 11 metastatic tumors, six were found to be positive for uropIakin III: metastatic colorectal adenocarcinoma, clear cell carcinoma of the kidney and embryonal carcinoma of testis.

Conclusion:
UP III Positivity for uroplakin III is not found only in primary bladder UC variants, but in some tumors that have metastatized to the bladder. Staining for uroplakin III alone should not be taken as evidence of UC.
Keyword Uroplakin III
Urinary bladder
Urothelial carcinoma
Metastases
Diagnosis
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 21 Dec 2014, 11:32:44 EST by System User on behalf of Discipline of Molecular and Cellular Pathology